Exclusive Online Content
Bioiberica Launches Natural Origin Thyroid
Bioiberica, a world reference in the identification, extraction, and development of animal-derived APIs, recently announced the launch of its natural thyroid active pharmaceutical ingredient (API) for the treatment of…..
Tetra Bio-Pharma Provides Update on its Hepatocellular Carcinoma Drug
Tetra Bio-Pharma Inc. recently announced it will be requesting a meeting with the US FDA to discuss the drug development program for its Orphan Drug candidate HCC011….
Catalent Partners With Bridge Therapeutics on Formulation, Development & Production of New Opioid Addiction Treatment
Catalent recently announced it has completed clinical production of Bridge Therapeutics Inc.’s (Bridge) opioid addiction development therapeutic product, BT-219, and executed an….
Diagnosed Prevalent Cases of Chronic Heart Failure to Reach 32 Million
Nearly 40% of all diagnosed prevalent cases of Chronic Heart Failure (CHF) in the eight major markets (8MM) occur in the elderly population, and this is estimated to increase by a further….
Tonix Pharmaceuticals Enrolls First Patient in Phase 3 RELIEF Study
Tonix Pharmaceuticals Holding Corp. recently announced that the first patient was enrolled in the Phase 3 RELIEF study (TNX-CY-F304)……
LEO Pharma and Portal Instruments Announce Collaboration to Develop Needle-Free Drug Delivery Device
LEO Pharma A/S and Portal Instruments recently announced a global collaboration and license agreement to develop Portal’s innovative needle-free drug delivery system for use in combination with….
Appili Therapeutics Enters Commercial Agreement With Saptalis Pharmaceuticals
Appili Therapeutics Inc. recently announced it has entered into a commercialization agreement with Saptalis Pharmaceuticals LLC on ATI-1501, Appili’s liquid suspension reformulation of the…..
Biogen Announces Positive Phase 2 Study Results
Biogen Inc. recently announced positive top-line results from the Phase 2 LILAC study evaluating the efficacy and safety of BIIB059, a fully humanized….
OWP Pharmaceuticals Announces Second IND Approval & Patent Application for First-Ever Liquid Oral Suspension Formulation
OWP Pharmaceuticals, Inc. recently announced today that it has received Investigational New Drug (IND) approval from the US FDA, and has submitted for US patent protection, for the first-ever liquid formulation of….
Encouraging Results of Pilot Study Testing Bionic Pancreas
Beta Bionics, Inc., a medical technology company developing and aiming to commercialize the world’s first fully automated bionic pancreas, recently announced its bionic pancreas glucose control algorithms that use lifelong autonomous learning were deployed in….
EXCLUSIVE ONLINE CONTENT
Bioiberica Launches Natural Origin Thyroid
Bioiberica, a world reference in the identification, extraction, and development of animal-derived APIs, recently announced the launch of its natural thyroid active pharmaceutical ingredient (API) for the treatment of…..
Tetra Bio-Pharma Provides Update on its Hepatocellular Carcinoma Drug
Tetra Bio-Pharma Inc. recently announced it will be requesting a meeting with the US FDA to discuss the drug development program for its Orphan Drug candidate HCC011….
Catalent Partners With Bridge Therapeutics on Formulation, Development & Production of New Opioid Addiction Treatment
Catalent recently announced it has completed clinical production of Bridge Therapeutics Inc.’s (Bridge) opioid addiction development therapeutic product, BT-219, and executed an….
Diagnosed Prevalent Cases of Chronic Heart Failure to Reach 32 Million
Nearly 40% of all diagnosed prevalent cases of Chronic Heart Failure (CHF) in the eight major markets (8MM) occur in the elderly population, and this is estimated to increase by a further….
Tonix Pharmaceuticals Enrolls First Patient in Phase 3 RELIEF Study
Tonix Pharmaceuticals Holding Corp. recently announced that the first patient was enrolled in the Phase 3 RELIEF study (TNX-CY-F304)……